KEGG   DRUG: D09315Help
Entry
D09315                      Drug                                   

Name
Canakinumab (genetical recombination) (JAN);
Canakinumab (USAN/INN);
Ilaris (TN)
Product
Formula
C6452H9958N1722O2010S42
Exact mass
145065.8205
Mol weight
145155.1643
Activity
Muckle-wells syndrome, rheumatoid arthritis, other inflammatory conditions [DS:H00282]
Remark
Therapeutic category: 
ATC code: 
Comment
Monoclonal antibody
Target
interleukin-1beta (IL1B) [HSA:3553] [KO:K04519]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04621  NOD-like receptor signaling pathway  
 
Interaction
Drug interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D09315  Canakinumab (genetical recombination) (JAN); Canakinumab (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC08 Canakinumab
      D09315  Canakinumab (genetical recombination) (JAN); Canakinumab (USAN/INN)
USP drug classification [BR:br08302]
 Immunological Agents
  Immunomodulators
   Canakinumab
    D09315  Canakinumab (genetical recombination) (JAN); Canakinumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  IL-1 family
   IL-1B [HSA:3553] [KO:K04519]
    Canakinumab [ATC:L04AC08]
     D09315  Canakinumab (genetical recombination) (JAN); Canakinumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
914613-48-2
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system